MMJ Recs

MARCH 23, 2024

However, challenges such as regulatory compliance costs and market saturation may affect the profitability of cannabis businesses. However, there are worries about increased cannabis use, particularly among young people, and potential impacts on mental health and road safety.

Legalization 52

Legalization Access Programs Education 52

MMJ Recs

APRIL 1, 2024

Its non-addictive nature and minimal side effects make it an attractive alternative to conventional pharmaceuticals for many individuals seeking natural remedies. Research on CBD’s Effectiveness Despite the growing interest in CBD’s therapeutic potential, more research is needed to fully understand its efficacy and safety profile.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JUNE 9, 2022

11:00-12:00 PM: Interstate Commerce: Impacts on markets, licensing, and consumer safety. 3:15-4:15 PM: Preventing Youth Access, Promoting Consumer Safety, & Protecting Public Health in State Markets. Panelists: Darrin Grondel, EdD, Vice President of Traffic Safety & Government Relations, Responsibility.org.

Policy 52

Policy Safety Seed-To-Sale Data 52

Canna Law Blog

FEBRUARY 23, 2020

.” In April 2019, Oklahoma passed Senate Bill 868 , which directs ODAFF, in consultation with the Governor and Attorney General to submit a hemp cultivation plan to the USDA to bring the state’s hemp program in compliance with the 2018 Farm Bill. Products containing Hemp CBD, other than pharmaceuticals approved by the FDA (i.e.,

Hemp 90

Hemp CBD Agriculture Cultivation 90

WeedAdvisor

JULY 21, 2019

South America needs safe, reliable growing materials, cannot use certain pesticides, needs to meet cleanliness and safety standards, etc. The production of pharmaceutical-grade cannabis is a highly specialised process — it is not as simple as planting a few marijuana seeds, harvesting the crop and turning it into medicine.”.

Conditions 60

Conditions Seed-To-Sale Compliance Compliance 60

Cannabis Law Report

JANUARY 24, 2022

Dr. Tucker joins Goldfinch Bio from Mirum Pharmaceuticals, where he served as Chief Medical Officer. During his tenure at Acerta, Dr. Tucker helped create and build the medical safety, quality, compliance and clinical development groups. Dr. Tucker is a member of the Royal College of Physicians (UK), and received his M.B.A.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JUNE 20, 2021

According to the World Health Organization, the toxicity of THC is “very low” compared to most other recreational and pharmaceutical drugs. CBD food products must be authorized by the Commission and undergo a pre-market safety assessment by the European Food Safety Authority (EFSA) before they can be legally marketed in the EU.

THC 105

THC CBD Food Safety 105

Cannabis Law Report

JANUARY 16, 2020

Devonian” or the “Corporation”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the signature of a lease Agreement with Hzb Pharma Canada Inc. Tweet this. About Devonian. Devonian Health Group Inc.

Extraction 64

Extraction Pharmaceutical Research and Development Terpenes 64

Cannabis Law Report

NOVEMBER 27, 2019

It is only through reasonable regulation that quality and safety be delivered to the public, and Folium believes the FDA must act against producers and distributors of CBD who do not meet quality and safety standards. CBD Isolate is a drug ingredient, as evidenced by GW Pharmaceutical’s Epidiolex product.

Hemp 59

Hemp Cannabinoids Supply Chain Pharmaceutical 59

NORML

JANUARY 11, 2019

Update : The Criminal Justice and Public Safety Committee will hold an executive session for HB 399 on 1/17 at 11am. The measure would allow Virginia’s licensed practitioners to recommend and pharmaceutical processors to dispense full therapeutic-strength medical cannabis oil. NH resident? New Hampshire. SC resident? Connecticut.

Legislation 191

Legislation Decriminalization Hemp Patients 191

Cannabis Law Report

SEPTEMBER 3, 2019

We are delighted to start working with this Licensed Producer, and others, who share our vision of providing the highest quality pharmaceutical-grade products. We are dedicated to making our compliance regimen second-to-none in Australia just as it is in Canada,” said Mr. McCutcheon.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Greenspoon Marder Cannabis Law Group Blog

JULY 18, 2019

Ability to meet the overall health needs of qualified patients and safety of the public. Measure 1, Security plan: The applicant shall provide an acceptable safety and security plan, including staffing and site plan, and a detailed description of proposed security and safety measures, which demonstrates compliance with the rules at N.J.A.C.

Law 40

Law Marijuana Education Safety 40

Cannabis Law Report

JULY 20, 2019

Ability to meet the overall health needs of qualified patients and safety of the public. Measure 1, Security plan: The applicant shall provide an acceptable safety and security plan, including staffing and site plan, and a detailed description of proposed security and safety measures, which demonstrates compliance with the rules at N.J.A.C.

Law 40

Law Marijuana Education Cultivation 40

Cannabis Law Report

JULY 28, 2021

The sol-gel technology is designed to deliver pharmaceutical compounds as a liquid at room temperature which becomes a gel at body temperature. The platform technology, which also includes a patent filing, was licensed to InnarisBio by UniQuest. Under the terms of the license, InnarisBio will receive exclusive rights in their desired fields.

Research and Development 98

Research and Development Programs Treatment Media 98

Cannabis Law Report

FEBRUARY 1, 2022

Medical cannabis and psychedelics are being increasingly recognised for their superior safety and efficacy compared to conventional pharmaceuticals. Left unaddressed, the toll on society will come at a huge cost and result not only in lost human capital wealth but a continuous spike of mental disorders, exacerbated by Covid-19.

Medicine 52

Medicine Pharmaceutical Cannabis Safety 52

WeedAdvisor

JUNE 19, 2019

and pharmaceutical research company, MedPharm holdings. With existing companies undergoing acquisitions and changes, along with foreign organizations entering the market, WeedAdvisor offers comprehensive business and government solutions to facilitate key functions, like compliance, safety and point of sale.

Medicine 53

Medicine Extraction Pharmaceutical Compliance 53

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

NOVEMBER 24, 2019

These events, amongst other drivers, have shown the obvious need to regulate product safety in CBD and THC products in a holistic and standardized way. In addition, the false sense of security and trust in product safety and control, is largely created by a lack of education and available information on the regulatory and enforcement side.

Business 95

Business Data Wellness and Beauty Safety 95

Cannabis Law Report

JUNE 1, 2021

Prior to UroGen, Mr. Barbera held various leadership roles at Dendreon Pharmaceuticals, Allergan, and Medimmune, among others. Sesen Bio remains committed to the health and safety of patients, caregivers and employees. Cautionary Note on Forward-Looking Statements.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

MARCH 26, 2022

His books include Ethical Business Practice and Regulation (Hart, 2017), Reform of Class and Representative Actions in European Legal Systems: A New Approach to Collective Redress in Europe (Hart, 2008), European Regulation of Consumer Product Safety (Oxford, 2005), Multi-Party Actions (Oxford, 2001), and European product liability (1993).

Cannabinoids 52

Cannabinoids Research and Development Supply Chain Policy 52

Cannabis Law Report

JUNE 14, 2019

This is a plant that not only improves people’s quality of life, it’s an alternative to sometimes dangerous pharmaceuticals and addictive opioids. It’s a medicine that an overwhelming majority of Floridians came together for, calling for constitutionally guaranteed access.”. Antoinette Duncan is the President and CEO of Duncan Life Sciences.

Agriculture 40

Agriculture Marijuana Research and Development Policy 40

Cannabis Law Report

JANUARY 21, 2019

There is significant real-world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products,” said said Dr. Mark Ware, chief medical officer at Canopy. We continue to follow our overall plan of self-sufficiency in Europe to be able to best provide individuals with high-quality medical cannabis.”.

Chronic Pain 72

Chronic Pain Medicine Education Patients 72

Cannabis Law Report

JUNE 26, 2019

Fried also strongly delivered a message that could have been taken straight out of my own mouth: “This is a plant that not only improves people’s quality of life, it’s an alternative to sometimes-dangerous pharmaceuticals and addictive opioids.” Zachary Kobrin. Antoinette Duncan. 15, Peter Barsoom.

Marijuana 65

Marijuana Agriculture Research and Development Education 65

Cannabis Law Report

AUGUST 19, 2019

Under EU law, in the interests of safeguarding public health, novel foods must undergo a safety assessment before they can be authorised for placing on the market. The European Food Standards Agency, which is responsible for food safety in the European Union, is currently considering the first novel food application for CBD.

Environment 45

Environment Food Seed-To-Sale Medicine 45

Cannabis Law Report

JUNE 10, 2021

–(BUSINESS WIRE)– CURE Pharmaceutical Holding Corp. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. OXNARD, Calif.–(BUSINESS

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

Cannabis Law Report

JANUARY 11, 2019

To further complicate matters, the authority responsible for pharmaceutical regulation, the Austrian Federal Office for Safety in Health Care explicitly does not regard CBD products as functional drugs and does not recognise it as a medicinal product.

Seed-To-Sale 49

Seed-To-Sale Food Hemp Oil 49

Canna Law Blog

SEPTEMBER 6, 2023

All of those clients have to deal with a myriad of healthcare law and regulatory issues under both federal and state law, and the cost of compliance is not cheap. The center doesn’t actually test drugs itself, although it does conduct limited research in the areas of drug quality, safety, and effectiveness standards.

Research and Development 113

Research and Development DEA Marijuana Pharmaceutical 113

Cannabis Law Report

JULY 24, 2019

March 25, 2019 posting – “CBD is being adopted more and more as a natural alternative to pharmaceutical-grade treatments for depression and anxiety.”. Office of Compliance. Office of Compliance. On your Twitter Social Media Account: • March 27, 2019 posting – “#ICBD to help lower anxiety.”. 360b, 360ccc, and 360ccc-l.

CBD 51

CBD Tincture Pets Chronic Pain 51

Cannabis Law Report

MARCH 29, 2020

This “zero recall” standard, the team said, was attributed to the fact that their cannabis product standards with regard to food safety and health was high and involved documentation of over 100 pages. . o Respondent checks: Age gates are in place to ensure compliance, and if underaged, then medical licenses must be checked.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE currently produces multiple commercial CBD oral film products in compliance with the 2018 U.S.Farm Bill and European regulations. CURE has partnerships in the U.S.,

DEA 59

DEA Pharmaceutical Research and Development Compliance 59

Cannabis Law Report

DECEMBER 23, 2019

It has been two years since California began licensing yet operators still struggle with compliance and are all still de facto, breaking one law or another. The FDA thereafter reaffirmed its long-standing position that CBD products intended for human consumption are illegal unless part of an approved pharmaceutical.

Law 59

Law Banking Hemp Retail 59

Cannabis Law Report

NOVEMBER 5, 2021

– Integrated solution provides a single platform for compliance with vaccination status tracking and weekly testing requirements – STONY BROOK, N.Y. & By providing both vaccine status management and weekly COVID-19 testing, the integrated platform offers a single solution for compliance with the ETS.

Compliance 52

Compliance Compliance Research and Development Therapy 52

Cannabis Law Report

MAY 1, 2019

9 Even under the Obama-era policy, Weedmaps might still be exposing itself to federal prosecution because it is not “demonstrably in compliance with [California’s] strong and effective. Even then, publishers should require that any cannabis-business certify its compliance with state and local laws. FOOTNOTES. & Prof. 47 U.S.C. §

Legalization 45

Legalization Business Law Cannabis 45

Cannabis Law Report

AUGUST 4, 2021

Eurofins CDMO is also planning to construct a new high potency Active Pharmaceutical Ingredient (API) facility, which is expected to be completed in April 2022, as well as a new large scale API plant in 2023 to accommodate increasing demand. It is expected to be completed in Q4 2021.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

OCTOBER 26, 2019

ii Non-clinical studiesAlthough the use of animals in research is separately regulated by each state and territory, all require compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes (Animal Code). However, the period of extension cannot exceed five years.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

SpeedWeed

JULY 8, 2021

Manufacturers have the best opportunity to build a brand, and this makes it an attractive part of the value chain for transplanted talent from liquor, packaged goods, and pharmaceuticals because it seems familiar. . He has spent his career working with and advising information companies in the compliance space.

Media 52

Media Data Retail Concentrates 52